Glaukos Corporation
General ticker "GKOS" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $6.0B (TTM average)
Glaukos Corporation follows the US Stock Market performance with the rate: 52.5%.
Estimated limits based on current volatility of 1.7%: low 174.99$, high 180.47$
Factors to consider:
- Total employees count: 1094 (+9.9%) as of 2025
- US accounted for 52.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Manufacturing disruptions, Product quality issues, Intellectual property risks, Cybersecurity threats
- Current price 28.9% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [76.80$, 139.31$]
- 2026-12-31 to 2027-12-31 estimated range: [67.82$, 126.55$]
Financial Metrics affecting the GKOS estimates:
- Negative: with PPE of -128.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.70 <= 0.28
- Positive: Interest expense per share per price, % of 0.07 <= 0.75
- Positive: Inventory ratio change, % of -1.94 <= -0.75
- Positive: -4.49 < Investing cash flow per share per price, % of -1.17
- Negative: negative Net income
Short-term GKOS quotes
Long-term GKOS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $314.71MM | $383.48MM | $507.44MM |
| Operating Expenses | $443.41MM | $505.85MM | $707.04MM |
| Operating Income | $-128.70MM | $-122.37MM | $-199.60MM |
| Non-Operating Income | $-5.03MM | $-23.23MM | $6.56MM |
| Interest Expense | $14.19MM | $10.04MM | $4.63MM |
| R&D Expense | $143.77MM | $150.65MM | $150.61MM |
| Income(Loss) | $-133.73MM | $-145.60MM | $-193.04MM |
| Taxes | $0.93MM | $0.77MM | $-5.35MM |
| Net Income(Loss)* | $-134.66MM | $-146.37MM | $-187.69MM |
| Stockholders Equity | $461.77MM | $766.93MM | $656.15MM |
| Inventory | $41.99MM | $57.68MM | $63.56MM |
| Assets | $940.41MM | $974.76MM | $893.49MM |
| Operating Cash Flow | $-57.76MM | $-61.32MM | $-46.34MM |
| Capital expenditure | $20.25MM | $6.30MM | $7.67MM |
| Investing Cash Flow | $14.10MM | $47.83MM | $-77.61MM |
| Financing Cash Flow | $15.04MM | $91.54MM | $11.89MM |
| Earnings Per Share** | $-2.78 | $-2.77 | $-3.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.